These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 34795387)

  • 1. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
    Wen J; Mao X; Cheng Q; Liu Z; Liu F
    Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.
    Li S; Li L; Pan T; Li X; Tong Y; Jin Y
    Front Immunol; 2022; 13():977016. PubMed ID: 36211383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer Analysis.
    Shen L; Chen Q; Yang C; Wu Y; Yuan H; Chen S; Ou S; Jiang Y; Huang T; Ke L; Mo J; Feng Z; Zhou P; Fan W
    Front Pharmacol; 2020; 11():593195. PubMed ID: 33384601
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of CD47 in tumor immunity: a potential target for combination therapy.
    Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
    Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
    Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
    BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of the
    Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
    Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.
    Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J
    Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.